PDE3A

cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A · Q14432 · PDE3A on Sugi Atlas →

296,934 patent compounds predicted against PDE3A, 208,661 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Anagrelide (SCHEMBL9411)	1.00	20/20
Revizinone (SCHEMBL27163)	0.50	19/20
Ethaverine (SCHEMBL25606)	1.00	10/20
Papaverine (SCHEMBL34702)	1.00	10/20
Cilostazol (SCHEMBL16128)	1.00	7/20
Zardaverine (SCHEMBL13334)	1.00	6/20
Olprinone (SCHEMBL27661)	1.00	6/20
Pimobendan (SCHEMBL27623)	0.84	6/20
SCHEMBL21550	0.48	6/20
SCHEMBL11520	0.46	5/20
Ibudilast (SCHEMBL30390)	1.00	4/20
SCHEMBL1190	0.90	4/20
SCHEMBL1833	0.82	4/20
SCHEMBL997	0.77	4/20
Doxecitine (SCHEMBL23178)	0.59	4/20
Lodenafil (SCHEMBL1058)	1.00	3/20
Sildenafil (SCHEMBL1895)	1.00	3/20
Gemcitabine (SCHEMBL4295)	1.00	3/20
Vardenafil (SCHEMBL5772)	1.00	3/20
Lamivudine (SCHEMBL33979)	1.00	3/20

Clinical trials — most relevant to PDE3A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study	PHASE4	COMPLETED
Switching of Sildenafil to Riociguat in CTEPH Patients	PHASE4	RECRUITING
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis	PHASE4	COMPLETED
Bosentan in Treatment of Pulmonary Arterial Hypertension	PHASE4	COMPLETED
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes	PHASE4	COMPLETED
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage	PHASE3	NOT_YET_RECRUITING
Chronic Sildenafil Treatment in Heart Failure	PHASE3	COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia	PHASE2/PHASE3	UNKNOWN
Efficacy of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Endoscopic Enucleation of Prostate	PHASE2/PHASE3	RECRUITING
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension	PHASE3	COMPLETED
Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer	PHASE3	RECRUITING
Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction	PHASE2/PHASE3	RECRUITING
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy	PHASE3	COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm	PHASE2	WITHDRAWN
Effect of Tadalafil on Cerebral Large Arteries in Stroke	PHASE2	COMPLETED
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)	PHASE2	RECRUITING
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)	PHASE1/PHASE2	COMPLETED
Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study	PHASE2	UNKNOWN
Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial	PHASE2	COMPLETED
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction	PHASE2	COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease	PHASE2	COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction	PHASE1	COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals	PHASE1	COMPLETED
Comparing The Effect of Tadalafil 5 mg/Day to Sildenafil 25 mg/Day on Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Erectile Dysfunction Patients; and Comparison of Clinical Response	EARLY_PHASE1	UNKNOWN
Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children	nan	COMPLETED
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy	nan	WITHDRAWN
Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones	nan	COMPLETED
Endurance Performance at Altitude	nan	COMPLETED
Safety and Efficacy of Tadalafil vs. Tadalafil With Sildosin in the Management of Moderately and Severely Symptomatic Patients of Prostatic Hyperplasia	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PDE3A binder may also engage these)

Protein	Name	Similarity
Q63085	—	0.997	Q63085 →
Q61409	—	0.997	Q61409 →
Q62865	—	0.995	Q62865 →
PDE3B	cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B	0.992	landscape →
Q9Z0X4	—	0.992	Q9Z0X4 →
Q1L8L6	—	0.987	Q1L8L6 →
O54828	—	0.986	O54828 →
A9ZLX4	—	0.984	A9ZLX4 →
Q2VPU4	—	0.984	Q2VPU4 →
Q5RHD1	—	0.983	Q5RHD1 →
Q96LU7	—	0.982	Q96LU7 →
Q62925	—	0.982	Q62925 →
Q5SGD7	—	0.981	Q5SGD7 →
Q9TUG2	—	0.980	Q9TUG2 →
P59672	—	0.980	P59672 →
O88974	—	0.979	O88974 →
O02810	—	0.979	O02810 →
Q28C33	—	0.979	Q28C33 →
Q6NRE7	—	0.979	Q6NRE7 →
Q6F6B3	—	0.978	Q6F6B3 →
O35589	—	0.978	O35589 →
Q9Y2I9	—	0.978	Q9Y2I9 →
P49140	—	0.978	P49140 →
Q924W7	—	0.978	Q924W7 →
Q62136	—	0.977	Q62136 →
P78524	—	0.977	P78524 →
Q4V7W5	—	0.977	Q4V7W5 →
Q8BMA3	—	0.977	Q8BMA3 →
Q8K4S7	—	0.977	Q8K4S7 →
A2A9T0	—	0.977	A2A9T0 →